CPRX

Catalyst Pharmaceuticals CPRX reported adjusted earnings of 79 cents per share for the first quarter of 2026, beating the Zacks Consensus Estimate of 64 cents. The company had recorded adjusted earnings of 68 cents in the year-ago quarter. Total revenues, the majority of which comprised product revenues, amounted to $149.4 million in the reported quarter, representing growth of 6% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $147 million. Catalyst Pharmaceuticals’ top line primarily comprised revenues from the sale of Firdapse, the first approved drug for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and the newer muscle disease drug, Agamree (vamorolone). Revenues generated from the sale of CPRX’s epilepsy drug Fycompa (perampanel) CIII also contributed to the top line. Firdapse generated sales worth $98.86 million in the reported quarter, up 18% year over year, driven by organic sales growth. The reported figure marginally missed the Zacks Consensus Estimate of $98.9 million. The drug has been witnessing strong demand, increasing prescription rates from LEMS patients and continued diagnosis of new LEMS patients. In 2023, Catalyst Pharmaceuticals acquired exclusive rights to manufacture and supply Agamree from Santhera Pharmaceuticals through a licensing agreement. In late 2023, the FDA approved Agamree for treating Duchenne Muscular Dystrophy in patients aged two years and older, which gave the company a third approved product. The drug was commercially launched in the United States in the middle of March 2024. In the reported quarter, Agamree generated revenues worth $36.7 million, up 67% year over year. The reported figure beat the Zacks Consensus Estimate of $35 million. Year to date, Catalyst Pharmaceuticals shares have gained 33.5% against the industry’s 4.7% decline. Image Source: Zacks Investment Research In 2023, Catalyst Pharmaceuticals acquired the U.S. rights for Fycompa (perampanel) CIII from Eisai Co., Ltd. This acquisition diversified the company’s portfolio by adding a commercial-stage epilepsy asset. Catalyst Pharmaceuticals started recording sales of Fycompa in 2023. Fycompa generated net product revenues of $13.8 million, down 61% year over year, as tablet generics began hitting the market in May 2025 following the expiration of its first U.S. patent, with another slated to expire in July...

Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026 CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today reported financial results for the first quarter of 2026 and provided a business update. Financial Highlights _________________________________ *Statements made in this press release include non-GAAP financial measures. Such information is provided as additional information and not as an alternative to Catalyst's financial statements presented in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures are intended to enhance an overall understanding of Catalyst's current financial performance. Catalyst believes that the non-GAAP financial measures presented in this press release provide investors and prospective investors with an alternative method for assessing Catalyst's operating results in a manner that Catalyst believes is focused on the performance of ongoing operations and provides a more consistent basis for comparison between periods. Non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP accounting. Further, non-GAAP measures of net income used by Catalyst may be different from and not directly comparable to similarly titled measures used by other companies. First Quarter 2026 Financial Highlights The Company delivered strong first quarter 2026 results. Total Q1 2026 product revenue, net was $149.3 million, a 5.6% year-over-year increase. Promoted products, FIRDAPSE® & AGAMREE®, totaled $135.6 million, a 28.2% year-over-year increase. FIRDAPSE Q1 2026 product revenue, net was $98.9 million, an 18.1% year-over-year increase, primarily driven by increases in sales volumes. AGAMREE Q1 2026 product revenue, net was $36.7 million, compared to product revenue, net of $22.0 million in Q1 2025. The results underscore continued sales volume growth and increasing prescriber engagement. FYCOMPA® Q1 2026 product revenue, net was $13.8 million, a 61.3% year-over-year decrease following loss of exclusivity in 2025. First Quarter 2026 Additional Financial Results Cost of sales: Cost of sales for the first quarter...

CORAL GABLES, Fla. (AP) — CORAL GABLES, Fla. (AP) — Catalyst Pharmaceutical Partners Inc. (CPRX) on Monday reported first-quarter profit of $63.7 million. On a per-share basis, the Coral Gables, Florida-based company said it had profit of 50 cents. Earnings, adjusted for pretax expenses and amortization costs, came to 79 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 64 cents per share. The specialty drug company posted revenue of $149.4 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $147.1 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CPRX at https://www.zacks.com/ap/CPRX

Catalyst Pharmaceuticals (CPRX) reported Monday Q1 adjusted earnings of $0.79 per diluted share, up

Catalyst Pharmaceutical (CPRX) reported $149.39 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 5.6%. EPS of $0.79 for the same period compares to $0.68 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $147.08 million, representing a surprise of +1.57%. The company delivered an EPS surprise of +23.44%, with the consensus EPS estimate being $0.64. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product revenue,net: $149.34 million versus $147.01 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change. Revenues- Product revenue, Net- FIRDAPSE: $98.86 million compared to the $98.94 million average estimate based on three analysts. The reported number represents a change of +18.1% year over year. Revenues- Product revenue, Net- AGAMREE: $36.71 million versus the three-analyst average estimate of $35.01 million. The reported number represents a year-over-year change of +66.6%. Revenues- Product revenue, Net- FYCOMPA: $13.77 million versus $13.07 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -61.4% change. Revenues- License and other: $0.05 million versus $0.1 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +123.8% change. View all Key Company Metrics for Catalyst here>>> Shares of Catalyst have returned +24.9% over the past month versus the Zacks S&P 500 composite's +9.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ca...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +23.44%. A quarter ago, it was expected that this specialty drug company would post earnings of $0.42 per share when it actually produced earnings of $0.68, delivering a surprise of +61.9%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Catalyst, which belongs to the Zacks Medical - Drugs industry, posted revenues of $149.39 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.57%. This compares to year-ago revenues of $141.42 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Catalyst shares have added about 33.5% since the beginning of the year versus the S&P 500's gain of 8.1%. While Catalyst has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Catalyst was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Bu...

United Therapeutics UTHR reported first-quarter 2026 earnings per share (EPS) of $5.82, which missed the Zacks Consensus Estimate of $6.73. Earnings decreased 12% year over year. United Therapeutics markets four products for pulmonary arterial hypertension (PAH): Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high-risk neuroblastoma. Revenues in the first quarter totaled $781.5 million, which missed the Zacks Consensus Estimate of $800 million. Revenues decreased 2% year over year. A key driver of the company’s top line is Tyvaso products. United Therapeutics markets two versions of Tyvaso: Tyvaso dry powder inhalation (DPI) and nebulized Tyvaso. Both versions are approved for the treatment of PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD) indications. Combined Tyvaso sales totaled $457.5 million, down 2% year over year due to lower revenues from nebulized Tyvaso. Tyvaso sales fell short of the Zacks Consensus Estimate of $469 million. Tyvaso DPI generated revenues of $330.3 million, climbing 9% year over year due to an increase in patient demand and some pricing benefits. Revenues from nebulized Tyvaso (treprostinil) were $127.2 million, down 22%, largely due to reduced U.S. demand and weaker international sales, despite modest price increases. Sales of Orenitram rose 12% year over year to $135.6 million, primarily driven by higher volumes sold. Remodulin (including Remunity Pump) sales declined 8% year over year to $126.6 million. Unituxin sales were down 8% year over year to $53.6 million. Adcirca sales were $2.9 million, down 52% year over year. Research and development expenses were $138.2 million in the quarter, down 7% year over year, mainly due to lower milestone payments for drug delivery device technologies, partly offset by higher personnel costs. Selling, general and administrative expenses increased 8% to $184.1 million in the quarter. As of March 31, 2026, UTHR had cash, cash equivalents and investments of $3.8 billion compared with $4.6 billion as of Dec. 31, 2025. The company had no debt. United Therapeutics Corporation price-consensus-eps-surprise-chart | United Therapeutics Corporation Quote United Therapeutics’ key phase III programs include Tyvaso in patients with various forms of chronic fibrosing interstitial lung disease (TETON studies) and oral...

The Company will Report First Quarter 2026 Financial Results on May 11, 2026 CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today. Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned. About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies. For more information, please visit Catalyst's website at www.catalystpharma.com. Forward-Looking Statements This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2025 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Cat...

Madrigal Pharmaceuticals MDGL reported first-quarter 2026 loss of $3.25 per share, narrower than the Zacks Consensus Estimate of a loss of $3.61. In the same quarter last year, the company had incurred a loss of $2.61 per share. In the first quarter, MDGL generated total revenues of $311.3 million, up significantly year over year, entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom), which was approved in 2024. The metric beat the Zacks Consensus Estimate of $301 million. Rezdiffra is the first marketed drug in MDGL’s portfolio, which was launched in April 2024 and posted significant year-over-year growth, driven by increased demand. Madrigal shares gained 7.4% on Wednesday, as investors were impressed by the better-than-expected earnings results. In March 2024, the FDA granted accelerated approval to Rezdiffra, making it the first and currently the only approved therapy for the MASH indication. The eligible patient population includes adults with noncirrhotic MASH with moderate to advanced liver fibrosis. Rezdiffra has also received conditional approval as the first and only therapy in the EU to treat adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis. Per Madrigal, more than 42,250patients are receiving the treatment as of March 31, 2026, up 2.5 times from first-quarter 2025, reflecting continued strong physician adoption and high patient demand. During the quarter, research and development expenses more than doubled to $108.7 million in the first quarter of 2026. The massive increase can be primarily attributed to one-time, upfront business development expenses of $54.3 million. Year to date, Madrigal shares have lost 7.3% against the industry’s 0.9% growth. Image Source: Zacks Investment Research Selling, general and administrative expenses also nearly doubled in the reported quarter to $268.5 million. This exponential rise was on account of increased commercial launch activities for Rezdiffra, including significant increases in headcount to support marketing efforts. Madrigal had cash, cash equivalents and marketable securities worth $817.9 million as of March 31, 2026, compared with $988.6 million as of Dec. 31, 2025. As the FDA and EU approved Rezdiffra under the accelerated pathway, the continued approval will be based on promising long-term safety and efficacy data...

Acadia Pharmaceuticals ACAD reported first-quarter 2026 earnings per share (EPS) of 2 cents, which missed the Zacks Consensus Estimate of 4 cents. In the year-ago quarter, the company had reported EPS of 11 cents. In the first quarter, Acadia recorded total revenues of $268.1 million, which missed the Zacks Consensus Estimate of $282 million. ACAD’s net product revenues comprise sales of its two marketed products, Nuplazid (pimavanserin) and Daybue (trofinetide). Acadia’s first drug, Nuplazid, is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACAD’s second product, Daybue, received approval in 2023 for treating Rett syndrome in adult and pediatric patients aged two years and older. The drug was launched in the United States in April 2023. Total revenues increased 10% year over year, driven by contributions from Daybue and continued growth in Nuplazid's market share. Year to date, Acadia shares have plunged 19.6% compared with the industry’s 1.6% decline. Image Source: Zacks Investment Research Revenues from Nuplazid increased 5% year over year to $167 million in the first quarter of 2026, driven primarily by volume growth. Nuplazid sales missed the Zacks Consensus Estimate of $179.7 million. Daybue recorded net product sales of $101 million in the reported quarter, up 20% year over year, driven by the growth in the drug’s unit sales as Acadia shipped to more unique patients. The reported figure, however, missed the Zacks Consensus Estimate of $105.6 million. Research and development (R&D) expenses were $76.9 million, down 2% year over year. Selling, general and administrative (SG&A) expenses were $171 million, up 35% year over year, due to increased marketing investments to support the continued growth of Nuplazid and Daybue. Acadia had cash, cash equivalents and investments worth $851 million as of March 31, 2026, compared with $820 million as of Dec. 31, 2025. Acadia continues to expect total revenues from the U.S. sales of its products to be in the range of $1.22-$1.28 billion in 2026. Nuplazid net product sales are expected to be in the range of $760-$790 million, while U.S. sales of Daybue are expected to be between $460 million and $490 million. R&D expenses in 2026 are projected to be in the range of $385-$410 million, while SG&A expenses are expected to be between $660 mi...

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +76.47%. A quarter ago, it was expected that this company would post earnings of $0.22 per share when it actually produced earnings of $0.24, delivering a surprise of +9.09%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Bioventus, which belongs to the Zacks Medical - Drugs industry, posted revenues of $132.09 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.26%. This compares to year-ago revenues of $123.88 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Bioventus shares have added about 43.6% since the beginning of the year versus the S&P 500's gain of 6%. While Bioventus has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Bioventus was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will...

BioMarin Pharmaceutical BMRN reported first-quarter 2026 adjusted earnings per share of 76 cents, missing the Zacks Consensus Estimate of 94 cents. However, earnings declined 33% year over year. This was largely due to a $31 million charge tied to the company’s unsuccessful campaign to extend Naglazyme manufacturing capabilities, as well as higher operating expenses associated with the acquisition of Amicus Therapeutics. Total revenues in the first quarter were $766.2 million, up 3% year over year. The figure beat the Zacks Consensus Estimate of $762.4 million. Shares of BioMarin were down in after-hours trading on Monday, likely due to the mixed earnings results. Year to date, the stock has lost about 7% compared with the industry’s 2% decline. Image Source: Zacks Investment Research Net product revenues totaled nearly $760.1 million, up 3.5% year over year on higher revenues from the company’s Enzyme Therapies, as well as Voxzogo. Royalty and other revenues totaled $6.1 million, down about 42% year over year. Voxzogo, approved for achondroplasia, generated sales of $220 million, up 3% year over year. Per the company, this modest upside was expected, as it had previously experienced large orders for the drug in the fourth quarter of 2025. Despite this, Voxzogo sales beat the Zacks Consensus Estimate of $216 million. BioMarin reports consolidated revenues from five products — Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim — under a single segment, “Enzyme Therapies.” Sales from this franchise increased 6% year over year to $514 million in the reported quarter, driven by higher product sales of Vimizim, Naglazyme and Brineura. Palynziq injection sales totaled $90 million in the quarter, down 3% year over year, impacted by order timing in the United States. The drug’s sales missed the Zacks Consensus Estimate of $112 million. Vimizim sales rose 12% year over year to $210 million, which beat the Zacks Consensus Estimate of $194 million. Naglazyme sales increased 14% year over year to $130 million. Brineura generated sales of $47 million, up 18%. Product revenues from Aldurazyme totaled $37 million, down 24% year over year. BioMarin signed a collaboration agreement with Sanofi’s SNY subsidiary, Genzyme, for Aldurazyme. SNY, through Genzyme, is BMRN’s sole customer for Aldurazyme. The Sanofi subsidiary is responsible for marketing and selling Aldurazyme to...